Drug Shows Promise Against Advanced Lung Cancer

BBC NewsDrug Shows Promise Against Advanced Lung CancerWebMDNivolumab -- marketed as Opdivo -- primarily helps patients whose tumor cells carry a trait that allows their cancer to avoid detection by the immune system. As a result, overall median survival was 12.2 months in the nivolumab group compared to 9.4 ...New immunotherapy drug outperforms chemotherapy for a form of lung cancerWashington PostLung cancer therapy is 'milestone'BBC NewsBristol's Opdivo cuts risk of lung cancer death for someReutersDeKalb Daily Chronicle -The Denver Postall 182 news articles »

Share this post